These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28536308)

  • 41. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.
    Slingluff CL; Petroni GR; Yamshchikov GV; Hibbitts S; Grosh WW; Chianese-Bullock KA; Bissonette EA; Barnd DL; Deacon DH; Patterson JW; Parekh J; Neese PY; Woodson EM; Wiernasz CJ; Merrill P
    J Clin Oncol; 2004 Nov; 22(22):4474-85. PubMed ID: 15542798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
    Gupta A; O'Cearbhaill RE; Block MS; Hamilton E; Konner JA; Knutson KL; Potts J; Garrett G; Kenney RT; Wenham RM;
    Gynecol Oncol; 2024 Oct; 189():90-97. PubMed ID: 39068739
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696).
    Schaefer C; Butterfield LH; Lee S; Kim GG; Visus C; Albers A; Kirkwood JM; Whiteside TL
    Int J Cancer; 2012 Aug; 131(4):874-84. PubMed ID: 22021080
    [TBL] [Abstract][Full Text] [Related]  

  • 46. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
    Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
    Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Granulocyte-macrophage colony-stimulating factor-based melanoma cell vaccines immunize syngeneic and allogeneic recipients via host dendritic cells.
    Schneeberger A; Lührs P; Kutil R; Steinlein P; Schild H; Schmidt W; Stingl G
    J Immunol; 2003 Nov; 171(10):5180-7. PubMed ID: 14607918
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
    Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
    Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
    Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
    J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
    Powell DJ; Rosenberg SA
    J Immunother; 2004; 27(1):36-47. PubMed ID: 14676632
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients.
    Atzpodien J; Fluck M; Reitz M
    Cancer Biother Radiopharm; 2004 Dec; 19(6):758-63. PubMed ID: 15665624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.
    Spearman P; Kalams S; Elizaga M; Metch B; Chiu YL; Allen M; Weinhold KJ; Ferrari G; Parker SD; McElrath MJ; Frey SE; Fuchs JD; Keefer MC; Lubeck MD; Egan M; Braun R; Eldridge JH; Haynes BF; Corey L;
    Vaccine; 2009 Jan; 27(2):243-9. PubMed ID: 18996425
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.
    Wang X; Dong A; Xiao J; Zhou X; Mi H; Xu H; Zhang J; Wang B
    Cell Mol Immunol; 2016 Nov; 13(6):850-861. PubMed ID: 26166767
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.
    Salerno EP; Shea SM; Olson WC; Petroni GR; Smolkin ME; McSkimming C; Chianese-Bullock KA; Slingluff CL
    Cancer Immunol Immunother; 2013 Jul; 62(7):1149-59. PubMed ID: 23657629
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
    Dang Y; Wagner WM; Gad E; Rastetter L; Berger CM; Holt GE; Disis ML
    Clin Cancer Res; 2012 Jun; 18(11):3122-31. PubMed ID: 22510348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
    van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial.
    Elias EG; Zapas JL; McCarron EC; Beam SL; Hasskamp JH; Culpepper WJ
    Cancer Biother Radiopharm; 2008 Jun; 23(3):285-91. PubMed ID: 18593361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study.
    Grotz TE; Kottschade L; Pavey ES; Markovic SN; Jakub JW
    Am J Clin Oncol; 2014 Oct; 37(5):467-72. PubMed ID: 23428946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.